B. Riley reaffirmed their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report sent to investors on Monday morning. They currently have a $220.00 price objective on the biopharmaceutical company’s stock.

ALNY has been the topic of a number of other reports. Credit Suisse Group boosted their target price on shares of Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the stock an outperform rating in a research report on Friday, November 3rd. Needham & Company LLC reaffirmed a buy rating and issued a $85.00 price target (down from $98.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 7th. Piper Jaffray Companies reaffirmed an overweight rating and issued a $14.71 price target (down from $188.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, November 2nd. Nomura started coverage on shares of Alnylam Pharmaceuticals in a report on Thursday, September 14th. They issued a reduce rating and a $56.00 price target on the stock. Finally, Chardan Capital reaffirmed a buy rating on shares of Alnylam Pharmaceuticals in a report on Monday, September 11th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and sixteen have given a buy rating to the stock. The company has an average rating of Buy and an average target price of $121.85.

Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down $1.29 during midday trading on Monday, hitting $126.91. 389,630 shares of the stock were exchanged, compared to its average volume of 1,144,818. Alnylam Pharmaceuticals has a twelve month low of $35.98 and a twelve month high of $147.63. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The firm had revenue of $17.10 million for the quarter, compared to analyst estimates of $28.15 million. During the same period in the previous year, the firm posted ($1.21) earnings per share. The company’s revenue for the quarter was up 24.8% on a year-over-year basis. equities research analysts anticipate that Alnylam Pharmaceuticals will post -5.21 earnings per share for the current year.

In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 74,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $126.86, for a total transaction of $9,387,640.00. Following the completion of the sale, the chief executive officer now owns 223,710 shares in the company, valued at $28,379,850.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Laurie Keating sold 30,000 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $135.89, for a total transaction of $4,076,700.00. Following the transaction, the senior vice president now owns 41,500 shares of the company’s stock, valued at approximately $5,639,435. The disclosure for this sale can be found here. In the last quarter, insiders have sold 393,212 shares of company stock valued at $48,109,436. 4.30% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the company. QS Investors LLC grew its position in shares of Alnylam Pharmaceuticals by 59.7% during the second quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock worth $192,000 after acquiring an additional 900 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Alnylam Pharmaceuticals by 7.0% during the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 167 shares during the last quarter. CIBC Asset Management Inc bought a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $221,000. Neuberger Berman Group LLC bought a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $229,000. Finally, Fayerweather Charles bought a new position in shares of Alnylam Pharmaceuticals during the third quarter worth about $230,000. Institutional investors and hedge funds own 88.43% of the company’s stock.

WARNING: This report was originally posted by Daily Political and is owned by of Daily Political. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.dailypolitical.com/2017/12/12/alnylam-pharmaceuticals-alny-given-buy-rating-at-b-riley.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.